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The expression of Ia antigen by various murine and human macrophage populations and the 
ability of prostaglandins of the E series to regulate Ia antigen expression were. explored. Monocytes 
and macrophages from human and murine populations demonstrated a dichotomy in the expres- 
sion of Ia antigen. Both human monocytes and macrophages expressed elevated levels of Ia 
antigen compared to their murine counterpart. Murine macrophages appear to express elevated 
levels of Ia antigen only when actively interacting with T lymphocytes in vivo or with lymphokines 
in vitro. Prostaglandins of the E series can suppress murine macrophage Ia antigen expression, 
but have little effect on the expression of Ia antigen by human monocytes and macrophages. Also, 
prostaglandins of the E series do not modulate the ability of human monocytes to present antigen 
to autologous lymphocytes when studied over a broad concentration range. These data suggest 
that prostaglandin E compounds do not profoundly a&ct human monocyte/macrophage Ia antigen 
expreSSiOn or human mOnOCyW. antigen presenting activity. 8 1986 Academic PITS., Inc. 
INTRODUCTION 
Metabolites of arachidonic acid are known to serve as potent regulatory compounds 
during episodes of acute and chronic inflammation (l-3). These lipid metabolites 
synthesized by cells at foci of inflammation, via both the lipoxygenase and cycloox- 
ygenase pathways, may exert their modulating activity by dictating immune cell activity 
(3-5). This observation has been recently supported by experiments demonstrating 
the ability of prostaglandins of the E series to influence macrophage/lymphocyte in- 
teraction, the key components in cell-mediated immune mechanisms (3,6). In studies 
from our laboratory we demonstrated that PGEi and PGF2, significantly influenced 
the in vivo kinetics of I-region-associated (Ia) antigen expression on murine immune 
granuloma macrophages (6), while investigations by Steeg et al. (7) showed that PGE 
can suppress lymphokine-induced Ia antigen expression by murine peritoneal mac- 
rophages. One of the major concerns of investigations involving mouse macrophages 
is the applicability of the data to human macrophage/monocyte systems. In the present 
study, we have investigated the effect of PGE compounds on Ia antigen expression 
and antigen presenting activity by human monocytes and have correlated these findings 
with the modulation of murine macrophage Ia antigen expression. 
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MATERIALS AND METHODS 
Isolation of blood mononuclear cells. Human and murine (CBA/J-H-2k) mononu- 
clear cells were isolated from anticoagulant blood using Ficoll-Hypaque density gra- 
dients, as previously described (8). Additional human venous blood was drawn for 
the isolation of autologous serum. The isolation of murine granuloma macrophages 
and preparation of murine lymphokine(s) were carried out as previously described 
(6). In addition, human alveolar macrophages were recovered and cultured using the 
procedure of Razma et al. (9). 
Culture of human and mouse mononuclear phagocytic cell populations. Mononuclear 
cells from the gradient interface were thoroughly washed with RPMI-1640 (Grand 
Island Biochemical, Inc., Grand Island, N.Y.) and finally resuspended in complete 
medium consisting of RPMI- 1640 with 5% autologous serum and 10 &ml gentamicin. 
The cells were applied to either 35-mm plastic culture plates (Corning Glass Works, 
Corning, N.Y.) or glass tissue culture chambers (Lab Tek, Miles Laboratories, Inc., 
Naperville, Ill.), the latter for the determination of Ia antigen expression. After ad- 
herence for 4 hr at 37°C the nonadherent cells were removed by washing with warm 
RPMI- 1640 and the adherent cells were either examined for Ia antigen expression or 
returned to the incubator in complete medium in the presence or absence of 1 ti 
PGE, (gift from Dr. John Pike, The Upjohn Co., Kalamazoo, Mich.). 
Assay for Ia antigen expression. All monocyte and macrophage populations were 
freshly isolated and allowed to adhere for 4 hr at 37°C in a 5% CO* humidified at- 
mosphere prior to assaying for initial Ia antigen expression. Adherent mononuclear 
phagocytic cells were quantitated and identified as macrophages by morphologic cri- 
teria, ability to ingest latex beads, and nonspecific esterase staining. After fixation with 
0.1% paraformaldehyde, all cells were washed with phosphate-buffered saline (PBS) 
containing 5% fetal calf serum (FCS) and 0.05% sodium azide. The human cells were 
then reacted with Ia monoclonal antibody (9) for 30 min, washed with PBS-5% FCS- 
0.05% sodium azide, and developed with fluoroscein labeled F(ab’h rabbit IgG directed 
against mouse IgG. Controls included an anti-B-cell antibody unreactive with mac- 
rophages ( 10) and a murine monoclonal antibody directed against Iab (American Type 
Culture Collection, Bethesda, Md.). Ia antigen expression by murine macrophages 
was assessed using monoclonal antibody directed against I-Ak described by Oi et al. 
( 11). Monoclonal anti I-Ab, described by Ozato and Sacks ( 12), was used as a control. 
, Clones synthesizing both murine I-A antibodies were purchased from the American 
Type Culture Collection. Fluoroscein-conjugated F(ab’)Z rabbit IgG directed against 
mouse IgG was used to label the bound I-A antibody. By ultraviolet microscopy a 
minimum of 200 cells were counted to determine the percentage of positive cells. 
Assay for antigen presentation. Adherent human blood monocytes were isolated as 
above, while nylon wool-purified T cells were prepared using a method previously 
described (13). Adherent cells (6 X 104) were incubated in the wells of a microtest 
plate in the presence of none, or various concentrations of PGE, , and 25 pg tetanus 
toxoid. Cells were incubated in a 37°C 5% CO* humidified incubator. After 4 days 
incubation, the cells were washed and 2 X 10’ nylon wool-purified T cells were added. 
At the end of a further 5-day incubation period, each well was pulsed with 2 &i of 
[3H]thymidine (sp act 6.7 Ci/mmole; New England Nuclear, Boston, Mass.). After 18 
hr, cultures were harvested using a multiple automated sample harvester (MASH I). 
Scintillation counting was performed in a Beckman liquid scintillation counter. 
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RESULTS 
la antigen expression by various human and mouse macrophage populations, The 
macrophage is known to be a key effector cell in the generation and maintenance of 
various chronic immune responses (14). The initiation of these macrophage/lympho- 
cyte-mediated cellular responses is dependent upon many molecular signals that can 
interact in an amplification loop leading to immune cell activation. Signals of lym- 
phocyte origin include various protein and peptide cytokines, while those of macro- 
phage origin include arachidonate metabolites, interleukin 1, and antigen class II (Ia) 
molecule presentation structures (3, 4, 15). Therefore, we initially wished to profile 
the capacity of various human and mouse macrophage populations to express Ia an- 
tigen. As shown in Table 1, a dichotomy exists between human and mouse macrophage 
Ia antigen expression. Normal mouse monocyte and macrophage populations expressed 
very low levels of Ia antigen unless specifically interacting with T lymphocytes, such 
as the case in hypersensitivity granulomatous inflammation. Conversely, human 
monocyte/macrophages from various sources normally express high levels of Ia-like 
antigen that do not significantly change during an inflammatory response (Table 1). 
Modulation of la-like antigen on mouse but not human macrophages by PGE,. 
Previous studies from our laboratory have demonstrated that in vitro PGEi treatment 
of murine macrophages can directly affect Ia antigen expression (6). Although the 
reduction in Ia antigen expression by lymphokine-treated murine macrophages at 
Days 1 and 2 followed by a rebound at Days 3 and 4 corroborates the findings of 
Beller and Ho (16), we have now shown that PGE, can modulate this expression of 
lymphokine-induced Ia antigen. As shown in Table 2, PGEi (1 PM) can suppress 
mouse Ia antigen expression IO-fold, while the percentage of antigen expression by 
human cells remained unaltered during the 4-day study period. In additional exper- 
iments, the expression of Ia antigen by mouse macrophages treated with lymphokine 
at time 0 and PGE, ( 1 PM) at Day 3 resulted in a reduction of macrophage Ia antigen 
expression on Day 4. Withholding PGE, treatment from the human macrophages 
until Day 3 had no effect on the expression of Ia-like antigen on Day 4. The refractory 
response of antigen expression by human macrophages to PGE, was also demonstrated 
using human alveolar and human peritoneal macrophages (data not shown). In ad- 
dition, PGEz had the identical effect as PGE, in the above system. 
TABLE 1 
Percentage of Macrophages Expressing Ia Antigen 




Pulmonary hypersensitivity granuloma 
65+ 15 1*4 
69 k 21 <5 
59 f 19 <5 
80 k 16’ 56 + lb 
Note. Comparison of the percentage of Ia antigen expression between freshly isolated human and mouse 
macrophages prepared from various sources. Means k SEM of four to seven experiments. Each experiment 
was performed in triplicate. 
D Granuloma macrophages were isolated from patients with pulmonary granulomatous sarcoidosis. 
b Granuloma macrophages were isolated from experimental murine schistosome egg delayed-type hyper- 
sensitivity pulmonary granulomatous lesions. 
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TABLE 2 









-PGE, +PGEi (lO+‘M) -PGE, +PGE, ( 10-6M) 
59+ 3 - 51+ 4 - 
64? 5 71+ 8 21+ 3 18 +6 
61+ 9 75 + 10 13+ 5 10*4 
78k 11 71+ 5 35-c 11 <5 
61 f 13 65+ 8 49* 9 <5 
Note. Effect of PGE, on the expression of Ia-like antigen by human peripheral blood monocytes and 
mu&e macrophages. PGEi did not significantly alter the expression of Ia-like antigen by human cells during 
the 4-day study period, while Ia expression on granuloma macrophages from the mouse was dramatically 
reduced by PGE, . Means + SEM of three experiments. Each experiment was performed in triplicate. 
’ Mouse macrophages were incubated in the presence of mouse spleen cell derived lymphokines from 
time 0 in order for Ia antigen to be reexpressed at Days 3 and 4; this expression was blocked by PGE, . 
Inability of PGE, to modulate antigen presenting function by human monocytes. 
The above studies demonstrated that PGEr does not appear to influence the expression 
of Ia antigen by cultured human monocytes. In order to assess the ability of PGEr to 
alter the functional role of Ia antigen-positive human monocytes, we examined the 
ability of this biologically active lipid to modulate monocyte-induced lymphocyte 
proliferation. Human monocytes were incubated in the presence of tetanus toxoid 
and various concentrations of PGE, for 96 hr. At this point the adherent cells were 
washed, and nylon wool-purified T cells wee added to culture such that the final ratio 
of adherent cells to T cells was 1:3. As shown in Fig. 1, PGEi at doses ranging from 
1 X lop6 to 1 X 10e9 M did not inhibit the ability of human monocytes to present 
antigen to T lymphocytes. The strict requirement for monocytes to express Ia antigen 
in order for lymphocytes to proliferate was demonstrated by the suppression of pro- 
liferation when monocytes were pretreated with antibody directed against the Ia antigen. 
Monocytes pretreated with antibody directed against Ia antigen and then used as 
antigen presenting cells could only induce 10-20s of the normal lymphocyte prolif- 
eration as untreated monocytes. These studies suggest that PGE may not play a mod- 
ulatory role in human monocyte/macrophage Ia antigen expression or antigen pre- 
sentation. 
DISCUSSION 
The mobilization of arachidonic acid from membrane-bound phospholipids and 
the conversion of this substrate via the lipoxygenase and/or cyclooxygenase pathways 
yield products with diverse biological activities (2, 17). Recent studies have demon- 
strated that products from the cyclooxygenase pathway can influence the development 
and regulation of immune responses and inflammatory reactions (17). These inves- 
tigations have centered around the in vivo use of prostaglandins of the E series to 
suppress acute and chronic inflammatory responses in experimental animals. Although 
the exact means by which PGE compounds attenuate inflammatory reactions are not 
fully understood, it is known the PGEs can down-regulate murine macrophage and 
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FIG. 1. Effect of various doses of PGE, on antigen presentation by adherent monocytes. Adherent cells 
were incubated in the presence of tetanus toxoid (25 pgg) and graded concentrations of PGE, . Afier a 4day 
incubation period the cells were washed and then cocultivated with T cells for 6 additional days. To demonstrate 
that the T-cell preparation was adequately depleted of monocytes, column-purified T cells were incubated 
for 6 days in the presence of tetanus toxoid but no additional source of monocytes (line 2). 
lymphocyte function ( 18). However, few studies have closely examined the ability of 
prostaglandins of the E series to regulate human monocyte/macrophage function(s) 
necessary to interact with T lymphocytes. In the present report we have examined the 
expression of Ia antigen by various mouse and human macrophage populations and 
have studied the ability of PGEs to regulate the expression of Ia antigen. In addition, 
the antigen presenting activity of cultured human monocytes was assessed in the pres- 
ence and absence of PGEs. 
Our results have demonstrated a dichotomy in the expression of Ia antigen between 
various human and murine macrophage populations. It is noteworthy that both human 
monocyte and macrophage populations express high levels of Ia antigen compared to 
their murine counterparts. Murine macrophages apparently only express high levels 
of Ia antigen in viva when actively interacting with T lymphocytes, as would be the 
case during delayed-type hypersensitivity reactions. Contrary to human macrophages, 
Ia antigen expression by murine macrophages in vitro is rapidly lost but can be reex- 
pressed by incubating with lymphokine preparations. 
In an extension of our earlier observations we provide evidence that PGEs can 
suppress murine macrophage Ia antigen expression in the preence of lymphokine, but 
PGEs do not alter the expression of Ia antigen by human monocytes and macrophages. 
In addition, PGEs do not modulate the ability of human monocytes to present antigen 
to autologous T lymphocytes when examined over a 4 log concentration range. Our 
results confirm and extend the studies of Mori and Hayward (19), whereby cultured 
human monocytes retained their ability to present antigen in association with Ia surface 
antigen. The persistence of Ia antigen expression by human monocytes may in part 
be due to their reduced rate of surface Ia antigen turnover (20). The mechanism(s) by 
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which human, but not murine, monocyte/macrophages remain refractory to the effects 
of PGEs with regard to Ia antigen expression and antigen presenting activity is not 
clear, but may be due to the in vivu interaction of macrophages with T-lymphocyte 
product(s) resulting in an altered state of immunological competence. Recent studies 
have demonstrated that human monocytes contaminated with T lymphocytes can 
express high levels of Ia-like antigen for up to 5 days (21), but thorough depletion of 
the T lymphocytes resulted in a decrease in the expression of Ia-like antigen. This 
latter phenomenon was reversed when y-interferon was substituted for the T lym- 
phocytes. In addition, PGEs have also been shown to down-regulate murine macro- 
phage function, as related to tumoricidal activity, but this suppression was not observed 
if macrophages were incubated with murine y-interferon, a potent lymphokine, prior 
to PGE exposure (22). Therefore, we feel that the continued expression of Ia-like 
antigen and the potential for antigen presentation by human monocytes and macro- 
phages, even in the presence of PGEs, may reflect prior stimulation with T-lymphocyte 
product(s) that is tonically secreted by human T cells. Further analyses are currently 
underway to delineate the mechanisms whereby other arachidonic acid metabolites 
may dictate macrophage/lymphocyte interactions. 
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